Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1.
gamma-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain. The synaptic action of GABA is terminated by rapid uptake into presynaptic terminals and surrounding glial cells. Molecular cloning has revealed the existence of four distinct GABA transporters termed GAT-1, GAT-2, GAT-3, and BGT-1. Pharmacological inhibition of transport provides a mechanism for increasing GABA-ergic transmission, which may be useful in the treatment of various neuropsychiatric disorders. Recently, a number of lipophilic GABA transport inhibitors have been designed and synthesized, which are capable of crossing the blood brain barrier, and which display anticonvulsive activity. We have now determined the potency of four of these compounds, SK&F 89976-A (N-(4,4-diphenyl-3-butenyl)-3-piperidinecarboxylic acid), tiagabine ((R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3- piperidencarboxylic acid), CI-966 ([1-[2-[bis 4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydro-3- pyridinecarboxylic acid), and NNC-711 (1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,4,6-tetrahydro-3- pyridinecarboxylic acid hydrochloride), at each of the four cloned GABA transporters, and find them to be highly selective for GAT-1. These data suggest that the anticonvulsant activity of these compounds is mediated via inhibition of uptake by GAT-1.
Borden
L A
LA
Department of Pharmacology, Synaptic Pharmaceutical Corporation, Paramus, NJ 07652.
Murali Dhar
T G
TG
Smith
K E
KE
Weinshank
R L
RL
Branchek
T A
TA
Gluchowski
C
C
D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000494:pharmacology*; D002352:Carrier Proteins / Q000096:biosynthesis / Q000187:drug effects*; D002460:Cell Line; D003001:Cloning, Molecular; D018756:GABA Antagonists / Q000737:chemistry / Q000494:pharmacology*; D050485:GABA Plasma Membrane Transport Proteins; D006801:Humans; D008565:Membrane Proteins / Q000096:biosynthesis / Q000187:drug effects*; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins / Q000096:biosynthesis / Q000187:drug effects*; D009539:Nicotinic Acids / Q000737:chemistry / Q000494:pharmacology*; D009557:Nipecotic Acids / Q000737:chemistry / Q000494:pharmacology*; D027361:Organic Anion Transporters; D010091:Oximes / Q000737:chemistry / Q000494:pharmacology*; D011725:Pyridines / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000187:drug effects; D013329:Structure-Activity Relationship; D000078308:Tiagabine; D014162:Transfection
D000927:Anticonvulsants; D002352:Carrier Proteins; D018756:GABA Antagonists; D050485:GABA Plasma Membrane Transport Proteins; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D009539:Nicotinic Acids; D009557:Nipecotic Acids; D027361:Organic Anion Transporters; D010091:Oximes; D011725:Pyridines; D011994:Recombinant Proteins; C493413:SLC6A1 protein, human; C493416:SLC6A11 protein, human; C493418:SLC6A13 protein, human; C493415:Slc6a1 protein, rat; C078793:NNC 711; C045598:N-(4,4-diphenyl-3-butenyl)nipecotic acid; C067012:CI 966; D000078308:Tiagabine